600267.SS
Strong BuyUnloved QualityAI screen passZhejiang Hisun Pharmaceutical Co., Ltd. · Healthcare · China · $2.0B
CNY 11.75 +2.8% · close 30 Sep · scored 7 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
The stock qualifies via composite scoring and shows positive momentum from upward EPS revisions. It fits the resilience theme within the healthcare sector as a stable compounder.
ABOUT ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
Read
Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures active pharmaceutical ingredients (APIs), generic formulations, and innovative biopharmaceuticals. The company maintains a strong competitive position through its extensive global regulatory certifications (FDA, CEP) and its advanced chemical synthesis capabilities. It is a leading, vertically integrated pharmaceutical exporter with a growing focus on high-margin biosimilars and oncology drugs.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.4B | 10.1B | 10.3B | 10.5B | -2.5% | 9.8B | 8.5B | 8.6B | -9.7% |
| EPS (CNY) | 0.41 | -0.08 | 0.52 | 0.46 | 4.1% | 0.75 | 0.64 | 0.57 | 11.3% |
| Shares | 1.2B | 1.2B | 1.2B | 1.2B | +0.1% | 1.2B | — | — | — |
| Debt | 6.1B | 5.7B | 4.2B | 3.1B | -20.6% | 1.8B | — | — | — |
| Equity | 8.1B | 8.1B | 8.3B | 8.6B | 2.1% | — | — | — | — |
| Op CF | 2.2B | 1.5B | 2.2B | 2.0B | -1.9% | 1.6B | — | — | — |
| Inv CF | -665.2M | -292.7M | -290.4M | -369.1M | — | — | — | — | — |
| Fin CF | -1.5B | -1.0B | -2.0B | -1.6B | — | — | — | — | — |
Calmer than 58% of stocks we rank over the past year (37% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600267.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 600267.SS | Zhejiang Hisun Pharmaceutical Co., Ltd.(you) | $2.0B | 94 | Strong Buy |
| 600750.SS | China Resources Jiangzhong Pharmaceutical Co.,Ltd | $2.1B | 90 | Strong Buy |
| 1513.HK | Livzon Pharmaceutical Group Inc. | $2.4B | 96 | Strong Buy |
| 600420.SS | Shanghai Shyndec Pharmaceutical Co., Ltd. | $1.6B | 91 | Strong Buy |
| 600216.SS | Zhejiang Medicine Co., Ltd. | $1.8B | 89 | Strong Buy |
| 600572.SS | Zhejiang CONBA Pharmaceutical Co.,Ltd. | $1.6B | 91 | Strong Buy |
| 600535.SS | Tasly Pharmaceutical Group Co., Ltd | $3.0B | 94 | Strong Buy |
| 600211.SS | Tibet Rhodiola Pharmaceutical Holding Co. | $1.8B | 88 | Strong Buy |
| 603456.SS | Zhejiang Jiuzhou Pharmaceutical Co., Ltd | $2.1B | 86 | Strong Buy |
| 600380.SS | Joincare Pharmaceutical Group Industry Co.,Ltd. | $2.5B | 90 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 53.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.